Kodak, now a pharma company, expects drugs to make up 30-40% of its future business – The Next Web

Eastman Kodak stock more than tripled on Tuesday after the company revealed a pivot to pharmaceuticals in support of the US response to the coronavirus pandemic.

According to the Wall Street Journal, Kodak will soon play a role in curbing the US’ reliance on medicines from outside sources like China  starting with producing ingredients for generic drugs like the Donald Trump-touted hydroxychloroquine. 

Kodak chief exec Jim Continenza told WSJ he expects basic pharma ingredients to eventually make up 30% to 40% of the company’s overall business.